Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Accounts Payables: 2023-2025

  • Zhengye Biotechnology Holding's Accounts Payables was N/A to -$209,176 in Q2 2025 from the same period last year, while for Jun 2025 it was -$209,176, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is 8.91% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Accounts Payables is -$209,176, which was down 103.55% from $5.9 million recorded in Q4 2024.
  • In the past 5 years, Zhengye Biotechnology Holding's Accounts Payables ranged from a high of $6.3 million in Q4 2023 and a low of -$209,176 during Q2 2025.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Accounts Payables value was $5.9 million (recorded in 2024), while the average stood at $4.0 million.
  • Data for Zhengye Biotechnology Holding's Accounts Payables shows a maximum YoY fell of 7.20% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Zhengye Biotechnology Holding's Accounts Payables stood at $6.3 million in 2023, then fell by 7.20% to $5.9 million in 2024, then reached -$209,176 in 2025.
  • Its Accounts Payables was -$209,176 in Q2 2025, compared to $5.9 million in Q4 2024 and $6.3 million in Q4 2023.